MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
Healthcare
$1.98 +2.02%
+$0.08 today
- Market cap
- $126.54M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
52W Low $1.19High $4.64
Volume 0.93M
Average 0.98M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$81.04M
FY 2025 · Annual
Investing Cash Flow
-$114.10M
FY 2025 · Annual
Financing Cash Flow
$69.51M
FY 2025 · Annual
+7141.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (202.12M) | (119.76M) | (9.06M) | (66.97M) | (74.62M) |
| Depreciation & Amortization | 11.26M | 11.87M | 9.65M | 7.54M | 5.52M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 23.13M | 20.44M | 18.37M | 29.44M | 14.29M |
| Change in Working Capital | 17.57M | (6.13M) | 53.32M | 1.39M | (28.33M) |
| Accounts Receivables | 12.7M | (45.84M) | 45.86M | 6.06M | (9.06M) |
| Inventory | (6.42M) | 55K | 230K | (2.19M) | (7.91M) |
| Accounts Payables | 7.13M | (10.86M) | 1.28M | (1.53M) | (280K) |
| Other Working Capital | 4.17M | 50.51M | 5.95M | (948K) | (11.08M) |
| Other Non-Cash Items | 6.33M | 6.63M | (150.48M) | (39.78M) | 2.1M |
| Operating Cash Flow | (143.83M) | (86.96M) | (78.21M) | (68.37M) | (81.04M) |
| Capital Expenditures | (6.2M) | (3.62M) | (1.76M) | (3.71M) | (1.91M) |
| Acquisitions (Net) | 0 | 0 | 64K | 0 | 11K |
| Purchases of Investments | (231.21M) | (120.6M) | (239.68M) | (77.18M) | (208.34M) |
| Sales of Investments | 200.8M | 194.94M | 161.3M | 190.03M | 96.14M |
| Other Investing Activities | 0 | 0 | 0 | 40.16M | 0 |
| Investing Cash Flow | (36.61M) | 70.72M | (80.08M) | 149.3M | (114.1M) |
| Debt Repayment | 0 | 0 | (157K) | 0 | 0 |
| Common Stock Issued | 117.82M | 1.09M | 1.17M | 3.44M | 129K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.96M | 574K | 149.35M | 960K | 69.39M |
| Financing Cash Flow | 122.78M | 1.66M | 150.36M | 960K | 69.51M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (57.66M) | (14.59M) | (7.93M) | 81.88M | (125.62M) |
| Free Cash Flow | (150.03M) | (90.58M) | (79.97M) | (72.08M) | (82.95M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$74.6M
+ D&A$5.5M
+ Stock-Based Comp$14.3M
+ Deferred Tax$0
- Working Capital-$28.3M
+ Other Non-Cash$2.1M
= Operating Cash Flow-$81.0M
- Capex-$1.9M
= Free Cash Flow-$83.0M
Analysis
FY2025 free cash flow is -$83.0M. FCF conversion is 111.2% of net income. Operating cash flow was -$81.0M, with capex of -$1.9M. The largest bridge item is Working Capital at -$28.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 3 | Initial statement of beneficial ownership | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 |
Does MGNX generate free cash flow?
MacroGenics, Inc. (MGNX) generated -$82.95M of free cash flow in fiscal 2025.
How much operating cash flow does MGNX produce?
Operating cash flow was -$81.04M, before capital expenditures of $1.91M.
Continue the stock analysis
Jump to another research area for this company.